Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.

ABSTRACT:

Background

Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP).

Methods

We conducted a 6-month prospective observational study on postmenopausal women with severe OP receiving treatment with romosozumab either alone (in patients naïve to treatment) or in combination with ongoing long-term denosumab (>2 years) or continuing ongoing denosumab alone (>2 years). We collected serum samples for bone turnover markers, bone modulators, and calcium phosphate metabolism at baseline, month 3 and month 6. BMD was assessed at baseline and after 6 months.

Results

Fifty-two postmenopausal women with OP were included in the study. Nineteen received romosozumab alone, 11 received romosozumab combined to on

SUBMITTER: Adami G 

PROVIDER: S-EPMC10972672 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature